Professor Stephane Heritier is a leading academic research statistician with expertise in the design and analysis of (complex) large-scale trials clinical trials gained over a 20+ year period. He worked previously at the NHMRC Clinical Trials Centre (2002-06) & the George Institute (2007-13), Sydney, and is now based at Monash University, Melbourne. Therapeutic areas of expertise include diabetes, cardiovascular and neurological diseases, critical care, anaesthesiology, and physiotherapy. He is recognised worldwide as an expert in adaptive designs since he was one of the first to design and analyse an adaptive phase II/III trial in paediatric dermatology (Hemangiol) accepted by regulators and published in NEJM. This study has now become a benchmark in confirmatory adaptive designs. Other statistical research interests include survival analysis, cluster randomized trials and robust biostatistics. He is an active member of the ACTA reference group on innovations in clinical trials. Heritier is a Chief Investigator on several NHMRC funded trials including REMAP-CAP, a Bayesian platform trial designed to evaluate what interventions best reduce mortality in patients with severe Community Acquired Pneumonia; ITACS, a large 2-arm trial assessing the impact of intravenous iron in anaemic patients having elective cardiac surgery; the STAREE-MIND trial ($2.7M) aiming at preventing cognitive decline in the elderly; and the Centre of Research Excellence in Clinical Trials Methodology AusTriM launched in 2020.  More recently he received funding from the ARC to develop new methods of estimation for complex survival analysis models (2022-24) and 2 MRFF grants for EMPACT, a Bayesian adaptive design in severe depression and FEISTY-II, a clinical trial in trauma patients. Heritier is involved in statistical consulting within the Faculty of Medicine and for other institutions including the pharmaceutical industry. He is the lead author of a book entitled "Robust Methods in Biostatistics" published in 2009 with 3 Swiss co-authors.